MASHINIi

Fractyl Health, Inc..

GUTS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Fractyl Health, Inc. is a biotechnology company focused on developing novel metabolic therapeutics for the treatment of type 2 diabetes (T2D) and obesity. Their primary focus is on developing and commercializing the Revita DMR (Duodenal Mucosal Resurfacing) system, a minimally invasive endoscopic pr...Show More

Ethical Profile

Mixed.

Fractyl Health focuses on therapies for type 2 diabetes and obesity. Its Revita DMR system achieved a 1.0% HbA1c reduction and -3.1 kg weight loss in clinical studies, with 84% maintaining weight loss for one year. The FDA granted Revita two Breakthrough Device Designations. Preclinical Rejuva gene therapy also shows promise in mouse models. However, information on therapy price accessibility or vulnerable population reach is not available. The company uses animal testing (mice, pigs) in preclinical development, a standard practice, but specific details on animal welfare policies or alternative testing investments are not publicly disclosed. Data on fair pay, ethical sourcing, environmental impact, or business conduct is also unavailable.

Value Scores

Better Health for All20
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

20

Fractyl Health's core products, Revita DMR and the developing Rejuva gene therapy, are entirely focused on treating Type 2 Diabetes and obesity, demonstrating a strong positive health impact. Clinical studies for Revita DMR showed statistically significant reductions in HbA1c (1.0% at 24 months), weight (-3.1 kg), and improved HDL.

1
, with 84% of patients maintaining weight loss for one year.
2
Preclinical data for Rejuva also indicated durable metabolic improvements.
3
The company has an outstanding safety record for Revita, with no device-related or serious adverse events observed in clinical studies (n=118).
4
and only mild adverse events (constipation, vitamin B12 deficiency) in the REVITA-1 study (n=34).
5
Preclinical models for Rejuva also showed a favorable safety profile with no observed toxicity.
6
The company actively conducts clinical trials, including an open-label feasibility study (REVITA-1) with 34 subjects.
7
and a planned Phase 1/2 study for RJVA-001 in Europe to evaluate safety, tolerability, and efficacy in adults with inadequately controlled T2D.
8
The company's R&D is focused on these health-improving therapeutics, but no specific percentage of R&D budget allocated to health improvement is provided.

Fair Money & Economic Opportunity

0

No evidence available to assess Fractyl Health, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence available to assess Fractyl Health, Inc. on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No evidence available to assess Fractyl Health, Inc. on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No evidence available to assess Fractyl Health, Inc. on Honest & Fair Business.

Kind to Animals

0

The provided articles confirm that Fractyl Health, Inc. conducts preclinical animal studies, specifically mentioning the use of mouse models for gene therapy research and Yucatan pigs for targeted delivery studies.

1
However, the articles do not provide any specific, quantifiable data regarding the number of animals used, the company's animal testing policies, the extent of non-animal testing methods employed, or any certifications related to animal welfare. Consequently, there is insufficient evidence to score any of the 'Kind to Animals' KPIs.

No War, No Weapons

0

The provided articles for Fractyl Health, Inc. (GUTS.US) focus on its core business of developing metabolic therapeutics for type 2 diabetes and obesity.

1
While one article mentions compliance with trade sanctions and embargoes,
2
this is a policy statement and not concrete evidence of zero sales or the volume/frequency of sales to embargoed regimes. Similarly, a speculative mention of 'potential breakthroughs in targeted metabolic therapies' as 'potentially dual-use' is an inference,
3
not a factual statement about the company's R&D investment in technologies with military applications. There is no explicit information or quantitative data regarding any involvement in arms manufacturing, military contracts, dual-use technologies with military applications, peacebuilding investments, or any other activities directly related to the 'No War, No Weapons' ethical value. Therefore, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

0

The provided articles, primarily focusing on financial and clinical highlights, do not contain specific, concrete data points for any of the Planet-Friendly Business KPIs. Article 2 explicitly states that sustainability data is currently unavailable for GUTS.US.

1
Therefore, no KPIs can be scored based on the evidence provided.

Respect for Cultures & Communities

0

No evidence available to assess Fractyl Health, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

0

No evidence available to assess Fractyl Health, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No evidence available to assess Fractyl Health, Inc. on Zero Waste & Sustainable Products.

Own Fractyl Health, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.